Company Filing History:
Years Active: 2015-2022
Title: Michael J Mealy: Innovator in Cognitive Impairment Treatment
Introduction
Michael J Mealy is a notable inventor based in Lejre, Denmark. He has made significant contributions to the field of pharmacology, particularly in the treatment of cognitive impairment. With a total of 3 patents to his name, Mealy's work focuses on innovative compounds that target serotonin receptors.
Latest Patents
One of his latest patents is for the compound 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine. This compound exhibits combined serotonin reuptake, 5-HT3, and 5-HT1A activity, making it a potential treatment for cognitive impairment, especially in patients suffering from depression. Another patent details the process for preparing this compound or its pharmaceutically acceptable salts. This process involves reacting specific compounds in the presence of a solvent, a base, and a palladium catalyst.
Career Highlights
Michael J Mealy is currently associated with H. Lundbeck A/S, a company renowned for its focus on brain diseases. His work at Lundbeck has allowed him to explore and develop innovative solutions for cognitive disorders, contributing to the advancement of mental health treatments.
Collaborations
Mealy has collaborated with notable colleagues such as Andre Faldt and Lone Munch Ringgaard. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic compounds.
Conclusion
Michael J Mealy's contributions to the field of cognitive impairment treatment through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in mental health therapies.